Advertisement

Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapy

Abstract

Renal cell carcinoma (RCC) is the 10th most common cancer in Western countries. The prognosis of metastatic disease is unfavorable but may be different according to several risk factors, such as histology and clinical features (Karnofsky performance status, time from nephrectomy, hemoglobin level, neutrophils and thrombocytes count, lactate dehydrogenase and calcium serum value, sites and extension of the disease). In this review, we focused on some recent developments in the use of immunotherapy, surgery and cryotherapy in the treatment of advanced disease. While RCC is unresponsive to chemotherapy, recent advances have emerged with the development of targeted agents and innovative immunotherapy-based treatments. Surgical resection remains the standard of care for patients with small renal lesions but in patients with significant comorbidities ablative therapies such as cryoablation and radiofrequency ablation may lead to local cancer control and avoid surgical complications and morbidity. In the setting of metastatic RCC, radical nephrectomy, or cytoreductive nephrectomy, is considered a palliative surgery, usually part of a multimodality treatment approach that requires systemic treatments.

Tumori 2017; 103(1): 15 - 21

Article Type: REVIEW

DOI:10.5301/tj.5000581

Authors

Alessia Mennitto, Elena Verzoni, Giuseppina Calareso, Carlo Spreafico, Giuseppe Procopio

Article History

Disclosures

Financial support: No financial support was received for this submission.
Conflict of interest: Giuseppe Procopio reports receiving fees for serving on advisory boards from Bayer, Bristol-Myers-Squibb, Ipsen, Janssen, and Novartis and lecture fees from Astellas and Pfizer. Elena Verzoni reports receiving fees for serving on advisory boards from Pfizer, Janssen, and Novartis.

This article is available as full text PDF.

  • If you are a Subscriber, please log in now.

  • Article price: Eur 36,00
  • You will be granted access to the article for 72 hours and you will be able to download any format (PDF or ePUB). The article will be available in your login area under "My PayPerView". You will need to register a new account (unless you already own an account with this journal), and you will be guided through our online shop. Online purchases are paid by Credit Card through PayPal.
  • If you are not a Subscriber you may:
  • Subscribe to this journal
  • Unlimited access to all our archives, 24 hour a day, every day of the week.

Authors

Affiliations

  • Genitourinary Unit, Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy
  • Department of Interventional Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan - Italy

Article usage statistics

The blue line displays unique views in the time frame indicated.
The yellow line displays unique downloads.
Views and downloads are counted only once per session.

No supplementary material is available for this article.